You are here
FDG PET/MR for the Assessment of Lymph Node Involvement in Lymphoma : Initial Results and Role of Diffusion-Weighted MR
Ivan Platzek, Bettina Beuthien-Baumann, Rainer Ordemann, Jens Maus, Georg Schramm, Hagen H. Kitzler, Michael Laniado, Jörg Kotzerke, Jörg van den Hoff
Original Research Article
Academic Radiology, In Press, Corrected Proof, Available online 30 July 2014
Rationale and Objectives
The purpose of this study was to evaluate the sensitivity and specificity of positron emission tomography/magnetic resonance imaging (PET/MR) with 18F-fluorodeoxyglucose (FDG) for nodal involvement in malignant lymphoma.
Materials and Methods
Twenty-seven patients with malignant lymphoma (16 men and 11 women; mean age, 45 years) were included in this retrospective study. The patients underwent FDG PET/MR after intravenous injection of FDG (176–357 MBq FDG, 282 MBq on average). Follow-up imaging and histology served as the standard of reference.
One-hundred and twenty-seven (18.1%) of 702 lymph node stations were rated as having lymphoma involvement based on the standard of reference. One-hundred and twenty-four (17.7%) of 702 lymph node stations were rated as positive by FDG PET/MR. The sensitivity and specificity of FDG PET/MR for lymph node station involvement were 93.8% and 99.4%.
FDG PET/MR is feasible for lymphoma staging and has a high sensitivity and specificity for nodal involvement in lymphoma. Comparison with PET/CT is necessary to determine whether FDG PET/MR can replace PET/CT for lymphoma staging.